Journal
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
Volume 30, Issue 4, Pages S14-S18Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.sder.2011.11.002
Keywords
basal cell carcinoma; treatment; Hedgehog signaling pathway; Smoothened inhibitors
Categories
Funding
- University of Louisville Continuing Health Sciences Education
- Global Academy for Medical Education
- Genentech, Inc.
Ask authors/readers for more resources
A number of therapies that target components of the Hedgehog signaling pathway currently are in clinical trials. The specific molecules that seem most promising in basal cell carcinoma and a number of other cancers are those that target the Smoothened transmembrane protein. The pivotal phase II trials have been completed on the Smoothened inhibitor known as GDC-0449; five other agents (BMS-833923, LDE225, LEQ506, IPI926, and TAK-441) have also shown promise in animal studies and early clinical trials and have shown some efficacy in a variety of cancers that are affected by the Hedgehog signaling pathway. Semin Cutan Med Surg 30:S14-S18 (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available